Exploring lipoprotein(a) and incident heart failure in cancer patients with anthracycline-associated neoplasms
Clicks: 3
ID: 323425
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #264 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Anthracyclines remain cornerstone therapy for ~2.7 million cancer patients annually, conferring up to 30% survival benefits. However, dose-dependent cardiotoxicity affects ~9% of patients, manifesting as heart failure (HF). Lipoprotein(a) [Lp(a)], a genetically determined biomarker, promotes oxidative stress and inflammation – key CTRCD pathways. Traditional categorisation of Lp(a) using arbitrary cut-offs risks information loss, particularly where baseline risks, treatment toxicity, and competing events interact complexly. Although elevated Lp(a) is associated with cardiovascular events overall, its role in oncology and interaction with cardiotoxicity remains unknown, supporting evaluation as a CTRCD marker. Purpose To explore baseline Lp(a) as a candidate biomarker of HF susceptibility following chemotherapy by (i) characterizing its distribution in anthracycline-eligible cancer patients and (ii) evaluating its association with HF across the full concentration range, rather than relying on cut-offs. Methods Observational cohort study using UK Biobank data including 3,775 participants with anthracycline-associated neoplasms. Baseline Lp(a) was measured pre-chemotherapy; prevalent HF cases were excluded. Primary outcome was incident HF, defined as composite of HF diagnosis, hospitalisation, or HF-death. Lp(a) distribution and HF incidence were evaluated by concentration ranges. Associations were examined using logistic regression with Lp(a) modelled continuously (per 1 standard deviation [SD]) and restricted cubic splines (RCS) to assess nonlinearity. Sensitivity analyses evaluated clinical thresholds (75, 100, 125 nmol/L). Results reported as odds ratios (ORs) with 95% confidence intervals (CI). Results In 3,775 patients, 121 incident HF events occurred (3.2%) over median follow-up of 10.2 years (interquartile range [IQR] 5.4–14.8). Lp(a) was right-skewed (median 21.4 [IQR 10.1-59.3] nmol/L). Highest absolute HF incidence occurred at lowest Lp(a) range (0–10 nmol/L: 4.15%), without monotonic increase across distribution. Each 1-SD increase in Lp(a) was associated with non-significant lower odds of HF (OR 0.85 [95% CI 0.69–1.04]; p=0.13), consistent with HF events clustering at lower Lp(a) ranges and risk plateau at higher levels rather than direct dose-response. RCS showed no nonlinearity (p=0.23). Sensitivity analyses using clinical cut-offs (75, 100, 125 nmol/L) produced inconsistent estimates with wide CI and poor discrimination. Conclusion In this exploratory analysis, baseline Lp(a) showed no linear or threshold association with incident HF post-chemotherapy. Higher HF incidence at very low Lp(a) levels is hypothesis-generating and may reflect Lp(a) as marker of underlying systemic vulnerability rather than protection. Findings support continuous Lp(a) modeling in cardio-oncology to capture risk heterogeneity and inform future, adequately powered studies for precision risk stratification amid growing global burden of CTRCD.
| Reference Key |
openalex_W7172244319
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | A S Stephanus, J Barreto, A C Sposito, L S F Carvalho, Y Tu, A Campos Staffico |
| Journal | European heart journal supplements : journal of the European Society of Cardiology |
| Year | 2026 |
| DOI |
10.1093/eurheartjsupp/suag097.035
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.